{"podcast":{"title":"Mesa News Today | 2 Min News | The Daily News Now!","slug":"mesa-news-today-2-min-news-the-daily-news-now-7559357","podcast_index_feed_id":7559357,"rss_url":"https://feeds.fastcast.ai/the-mesa-daily-news-now.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/podcasts/the-mesa-daily-news-now.jpg","author":"The Daily News Now!","episode_count":901,"summary":"Hosted by Corey with the Story, Mesa News Today delivers fast, focused daily updates on the stories shaping Mesa—from local news and business to culture, sports, and community developments. Designed for quick, on-the-go listening, each episode brings you up to speed in minutes. Produced by AI for speed, consistency, and global scale, the show is part of The Daily News Now network—bringing local news to every city in the world and keeping communities connected. Mesa News Today is your daily snapshot of what’s happening in your city. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-07-24T14:18:43.264316+00:00","page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357"},"episode":{"title":"GLP-1 Drugs Revolutionizing Weight and Health | Mesa News","slug":"glp-1-drugs-revolutionizing-weight-and-health-mesa-news","published_at":"2026-07-10T19:54:24+00:00","page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357/glp-1-drugs-revolutionizing-weight-and-health-mesa-news","show_page_url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357","url":"https://sources.thednn.ai/cc355c23d078f93e","audio_url":"https://api.fastcast.ai/audio/718768be-249e-4c0d-b59a-646af0ebca8e.mp3","summary":"GLP-1 drugs like Ozempic and Wegovy are revolutionizing weight loss and chronic disease prevention, with 11% of adults now using them—up from just 3% two years ago. Awareness has skyrocketed, with 91% of people now familiar with these medications, a trend fueled by FDA approvals. Public health is seeing real shifts: the adult obesity rate has dropped from nearly 40% to 36%, while diabetes diagnoses have stabilized since 2023. Most users still rely on brand-name versions (68%), but compounded alternatives (19%) are gaining traction for affordability. Whether you’re on brand or compounded, the impact is clear—these drugs help regulate blood sugar, curb appetite, and are reshaping how we think about health and wellness. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/cc355c23d078f93e","meta_description":"GLP-1 drugs like Ozempic and Wegovy are revolutionizing weight loss and chronic disease prevention, with 11% of adults now using them—up from just 3% two…","key_points":[],"chapters":[],"topics":[],"duration_seconds":107,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/mesa-news-today-2-min-news-the-daily-news-now-7559357/episodes/glp-1-drugs-revolutionizing-weight-and-health-mesa-news/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/mesa-news-today-2-min-news-the-daily-news-now-7559357/glp-1-drugs-revolutionizing-weight-and-health-mesa-news.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}